Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO

BACKGROUND: Patients with recurrent/metastatic endometrial cancer that progresses after chemotherapy have limited treatment options and poor outcomes. Preclinical data suggest the oral mammalian target of rapamycin inhibitor everolimus may provide clinical benefit in these patients. METHODS: In this...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Ray-Coquard, I, Favier, L, Weber, B, Roemer-Becuwe, C, Bougnoux, P, Fabbro, M, Floquet, A, Joly, F, Plantade, A, Paraiso, D, Pujade-Lauraine, E
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2013
Предметы:
Clinical Study
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3658508/
https://ncbi.nlm.nih.gov/pubmed/23612453
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.183
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы